Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 238757, 9 pages
http://dx.doi.org/10.1155/2015/238757
Review Article

Genomic and Histopathological Tissue Biomarkers That Predict Radiotherapy Response in Localised Prostate Cancer

1Division of Clinical Studies, The Institute of Cancer Research, London SM2 5NG, UK
2Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, UK
3Division of Cancer Biology, The Institute of Cancer Research, London SM2 5NG, UK

Received 1 April 2015; Accepted 24 May 2015

Academic Editor: Franco M. Buonaguro

Copyright © 2015 Anna Wilkins et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. D. Grossfeld, D. M. Latini, D. P. Lubeck et al., “Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE,” Urology, vol. 59, no. 4, pp. 560–565, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. Z. S. Zumsteg, D. E. Spratt, I. Pei et al., “A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy,” European Urology, vol. 64, no. 6, pp. 895–902, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. C. West, B. S. Rosenstein, J. Alsner et al., “Establishment of a radiogenomics consortium,” International Journal of Radiation Oncology Biology Physics, vol. 76, no. 5, pp. 1295–1296, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. D. T. Goodhead, “Energy deposition stochastics and track structure: what about the target?” Radiation Protection Dosimetry, vol. 122, no. 1–4, pp. 3–15, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. R. C. Taylor, S. P. Cullen, and S. J. Martin, “Apoptosis: controlled demolition at the cellular level,” Nature Reviews Molecular Cell Biology, vol. 9, no. 3, pp. 231–241, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Chu, N. Teele, M. W. Dewey, N. Albright, and W. C. Dewey, “Computerized video time lapse study of cell cycle delay and arrest, mitotic catastrophe, apoptosis and clonogenic survival in irradiated 14-3-3sigma and CDKN1A (p21) knockout cell lines,” Radiation Research, vol. 162, no. 3, pp. 270–286, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. K. R. Luoto, R. Kumareswaran, and R. G. Bristow, “Tumor hypoxia as a driving force in genetic instability,” Genome Integrity, vol. 4, no. 1, article 5, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Bristow, A. Berlin, and A. Dal Pra, “An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy,” The British Journal of Radiology, vol. 87, no. 1035, 2014. View at Publisher · View at Google Scholar
  9. D. J. Brenner and E. J. Hall, “Fractionation and protraction for radiotherapy of prostate carcinoma,” International Journal of Radiation Oncology, Biology, Physics, vol. 43, no. 5, pp. 1095–1101, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Dearnaley, I. Syndikus, G. Sumo et al., “Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial,” The Lancet Oncology, vol. 13, no. 1, pp. 43–54, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. V. J. Gnanapragasam, “Molecular markers to guide primary radical treatment selection in localized prostate cancer,” Expert Review of Molecular Diagnostics, vol. 14, no. 7, pp. 871–881, 2014. View at Publisher · View at Google Scholar
  12. T. Sequeiros, M. García, M. Montes et al., “Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues,” BioMed Research International, vol. 2013, Article ID 283635, 15 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. B. Zhang, J. Wang, X. Wang et al., “Proteogenomic characterization of human colon and rectal cancer,” Nature, vol. 513, no. 7518, pp. 382–387, 2014. View at Publisher · View at Google Scholar
  14. F. McCarthy, N. Dennis, P. Flohr, S. Jhavar, C. Parker, and C. S. Cooper, “High-density tissue microarrays from prostate needle biopsies,” Journal of Clinical Pathology, vol. 64, no. 1, pp. 88–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Kachroo, A. Y. Warren, and V. J. Gnanapragasam, “Multi-transcript profiling in archival diagnostic prostate cancer needle biopsies to evaluate biomarkers in non-surgically treated men,” BMC Cancer, vol. 14, no. 1, article 673, 2014. View at Publisher · View at Google Scholar
  16. A. D. Pra, E. Lalonde, J. Sykes et al., “TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair,” Clinical Cancer Research, vol. 19, no. 18, pp. 5202–5209, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. L.-Y. Khor, K. Bae, R. Paulus et al., “MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02,” Journal of Clinical Oncology, vol. 27, no. 19, pp. 3177–3184, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Cowen, P. Troncoso, V. S. Khoo et al., “Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy,” Clinical Cancer Research, vol. 8, no. 5, pp. 1148–1154, 2002. View at Google Scholar · View at Scopus
  19. R. Li, K. Heydon, M. E. Hammond et al., “Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in Radiation Therapy Oncology Group Protocol 86-10,” Clinical Cancer Research, vol. 10, no. 12, part 1, pp. 4118–4124, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Pollack, M. Desilvio, L.-Y. Khor et al., “Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group trial 92-02,” Journal of Clinical Oncology, vol. 22, no. 11, pp. 2133–2140, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Verhoven, Y. Yan, M. Ritter et al., “Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08,” International Journal of Radiation Oncology Biology Physics, vol. 86, no. 2, pp. 317–323, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Vergis, C. M. Corbishley, K. Thomas et al., “Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation,” International Journal of Radiation Oncology, Biology, Physics, vol. 78, no. 1, pp. 35–41, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. D. S. Scherr, E. D. Vaughan Jr., J. Wei et al., “bcl-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy,” Journal of Urology, vol. 162, no. 1, pp. 12–17, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. L.-Y. Khor, M. DeSilvio, T. Al-Saleem et al., “MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group protocol 8610,” Cancer, vol. 104, no. 5, pp. 962–967, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. D. J. Grignon, R. Caplan, F. H. Sarkar et al., “p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610,” Journal of the National Cancer Institute, vol. 89, no. 2, pp. 158–165, 1997. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Che, M. DeSilvio, A. Pollack et al., “Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202,” International Journal of Radiation Oncology Biology Physics, vol. 69, no. 4, pp. 1117–1123, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. M. A. Ritter, K. W. Gilchrist, M. Voytovich, R. J. Chappell, and B. M. Verhoven, “The role of p53 in radiation therapy outcomes for favorable-to-intermediate-risk prostate cancer,” International Journal of Radiation Oncology, Biology, Physics, vol. 53, no. 3, pp. 574–580, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Chakravarti, K. Heydon, C. L. Wu et al., “Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10,” Journal of Clinical Oncology, vol. 21, no. 17, pp. 3328–3334, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Chakravarti, M. DeSilvio, M. Zhang et al., “Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group protocol 9202,” Journal of Clinical Oncology, vol. 25, no. 21, pp. 3082–3089, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Kirschenbaum, X.-H. Liu, S. Yao, and A. C. Levine, “The role of cyclooxygenase-2 in prostate cancer,” Urology, vol. 58, no. 2, supplement 1, pp. 127–131, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. Y.-M. Kim, Y. K. Shin, H. J. Jun, S. Y. Rha, and H. Pyo, “Systematic analyses of genes associated with radio sensitizing effect by celecoxib, a specific cyclooxygenase-2 inhibitor,” Journal of Radiation Research, vol. 52, no. 6, pp. 752–765, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. L.-Y. Khor, K. Bae, A. Pollack et al., “COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial,” The Lancet Oncology, vol. 8, no. 10, pp. 912–920, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Pollack, J. J. Dignam, D. A. Diaz et al., “A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02,” Clinical Cancer Research, vol. 20, no. 24, pp. 6379–6388, 2014. View at Publisher · View at Google Scholar
  34. L. Pan, S. Baek, P. R. Edmonds et al., “Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of Radiation Therapy Oncology Group (RTOG) 8610,” Radiation Oncology, vol. 8, no. 1, article 100, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Vergis, C. M. Corbishley, A. R. Norman et al., “Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study,” The Lancet Oncology, vol. 9, no. 4, pp. 342–351, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. M. M. L. Green, C. T. Hiley, J. H. Shanks et al., “Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome,” International Journal of Radiation Oncology Biology Physics, vol. 67, no. 1, pp. 84–90, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. M. I. Koukourakis, A. Giatromanolaki, M. Panteliadou et al., “Lactate dehydrogenase 5 isoenzyme overexpression defines resistance of prostate cancer to radiotherapy,” British Journal of Cancer, vol. 110, no. 9, pp. 2217–2223, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. D. T. Denhardt and X. Guo, “Osteopontin: a protein with diverse functions,” The FASEB Journal, vol. 7, no. 15, pp. 1475–1482, 1993. View at Google Scholar · View at Scopus
  39. L.-Y. Khor, K. Bae, T. Al-Saleem et al., “Protein kinase A RI-α predicts for prostate cancer outcome: analysis of Radiation Therapy Oncology Group trial 86-10,” International Journal of Radiation Oncology, Biology, Physics, vol. 71, no. 5, pp. 1309–1315, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. J. F. Torres-Roca, M. DeSilvio, L. B. Mora et al., “Activated STAT3 as a correlate of distant metastasis in prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 86-10,” Urology, vol. 69, no. 3, pp. 505–509, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Fosså, W. Lilleby, S. D. Fosså, G. Gaudernack, G. Torlakovic, and A. Berner, “Independent prognostic significance of Her-2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy,” International Journal of Cancer, vol. 99, no. 1, pp. 100–105, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. D. C. Weber, J.-C. Tille, C. Combescure et al., “The prognostic value of expression of HIF1α, EGFR and VEGF-A, in localized prostate cancer for intermediate- and high-risk patients treated with radiation therapy with or without androgen deprivation therapy,” Radiation Oncology, vol. 7, no. 1, article 66, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Pollack, D. Cowen, P. Troncoso et al., “Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x,” Cancer, vol. 97, no. 7, pp. 1630–1638, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Y. Khor, J. Moughan, T. Al-Saleem et al., “Bcl-2 and bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on Radiation Therapy Oncology Group protocol 92–02,” Clinical Cancer Research, vol. 13, no. 12, pp. 3585–3590, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. P. Bouchaert, S. Guerif, C. Debiais, J. Irani, and G. Fromont, “DNA-PKcs expression predicts response to radiotherapy in prostate cancer,” International Journal of Radiation Oncology Biology Physics, vol. 84, no. 5, pp. 1179–1185, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. J. W. Thoms, A. dal Pra, P. H. Anborgh et al., “Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response,” British Journal of Cancer, vol. 107, no. 5, pp. 840–846, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. A. X. Meng, F. Jalali, A. Cuddihy et al., “Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells,” Radiotherapy and Oncology, vol. 76, no. 2, pp. 168–176, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Kumareswaran, O. Ludkovski, A. Meng, J. Sykes, M. Pintilie, and R. G. Bristow, “Chronic hypoxia compromises repair of DNA double-strand breaks to drive genetic instability,” Journal of Cell Science, vol. 125, no. 1, pp. 189–199, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. N. Chan, M. Koritzinsky, H. Zhao et al., “Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance,” Cancer Research, vol. 68, no. 2, pp. 605–614, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. S. M. Falzarano, M. Zhou, P. Carver et al., “ERG gene rearrangement status in prostate cancer detected by immunohistochemistry,” Virchows Archiv, vol. 459, no. 4, pp. 441–447, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. T. A. Swanson, S. A. Krueger, S. Galoforo et al., “TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer,” The Prostate, vol. 71, no. 14, pp. 1548–1558, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Pollack, G. K. Zagars, A. K. El-Naggar, M. D. Gauwitz, and N. H. A. Terry, “Near-diploidy: a new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy,” Cancer, vol. 73, no. 7, pp. 1895–1903, 1994. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Song, W. S. Cheng, R. E. Cupps, J. D. Earle, G. M. Farrow, and M. M. Lieber, “Nuclear deoxyribonucleic acid content measured by static cytometry: important prognostic association for patients with clinically localized prostate carcinoma treated by external beam radiotherapy,” The Journal of Urology, vol. 147, no. 3, pp. 794–797, 1992. View at Google Scholar · View at Scopus
  54. G. Zafarana, A. S. Ishkanian, C. A. Malloff et al., “Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy,” Cancer, vol. 118, no. 16, pp. 4053–4062, 2012. View at Publisher · View at Google Scholar
  55. J. A. Locke, G. Zafarana, A. S. Ishkanian et al., “NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy,” Clinical Cancer Research, vol. 18, no. 1, pp. 308–316, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Berlin, E. Lalonde, J. Sykes et al., “NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer,” Oncotarget, vol. 5, no. 22, pp. 11081–11090, 2014. View at Google Scholar
  57. J. A. Locke, G. Zafarana, C. A. Malloff et al., “Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancer,” The Prostate, vol. 72, no. 12, pp. 1295–1305, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. S. J. Freedland, L. Gerber, J. Reid et al., “Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy,” International Journal of Radiation Oncology, Biology, Physics, vol. 86, no. 5, pp. 848–853, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. E. Lalonde, A. S. Ishkanian, J. Sykes et al., “Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study,” The Lancet Oncology, vol. 15, no. 13, pp. 1521–1532, 2014. View at Publisher · View at Google Scholar
  60. L.-Y. Khor, M. Desilvio, R. Li et al., “Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10,” International Journal of Radiation Oncology Biology Physics, vol. 66, no. 1, pp. 25–30, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. F. A. Stewart and A. van der Kogel, “Proliferative and cellular organization of normal tissues,” in Basic Clinical Radiobiology, G. G. Steel, Ed., pp. 23–29, Arnold, London, UK, 2002. View at Google Scholar
  62. J. W. Hopewell, J. Nyman, and I. Turesson, “Time factor for acute tissue reactions following fractionated irradiation: a balance between repopulation and enhanced radiosensitivity,” International Journal of Radiation Biology, vol. 79, no. 7, pp. 513–524, 2003. View at Publisher · View at Google Scholar · View at Scopus
  63. G. M. Morris and J. W. Hopewell, “Changes in the cell kinetics of pig epidermis after repeated daily doses of X rays,” British Journal of Radiology. Supplement, vol. 19, pp. 34–38, 1986. View at Google Scholar · View at Scopus
  64. I. Turesson and H. D. Thames, “Repair capacity and kinetics of human skin during fractionated radiotherapy: erythema, desquamation, and telangiectasia after 3 and 5 year's follow-up,” Radiotherapy and Oncology, vol. 15, no. 2, pp. 169–188, 1989. View at Publisher · View at Google Scholar · View at Scopus
  65. J. Thacker and R. E. Wilkinson, “The genetic basis of cellular recovery from radiation damage: response of the radiosensitive irs lines to low-dose-rate irradiation,” Radiation Research, vol. 144, no. 3, pp. 294–300, 1995. View at Publisher · View at Google Scholar · View at Scopus
  66. N. Somaiah, J. Yarnold, A. Lagerqvist, K. Rothkamm, and T. Helleday, “Homologous recombination mediates cellular resistance and fraction size sensitivity to radiation therapy,” Radiotherapy and Oncology, vol. 108, no. 1, pp. 155–161, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. N. Somaiah, J. Yarnold, F. Daley et al., “The relationship between homologous recombination repair and the sensitivity of human epidermis to the size of daily doses over a 5-week course of breast radiotherapy,” Clinical Cancer Research, vol. 18, no. 19, pp. 5479–5488, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. D. L. Rimm, “What brown cannot do for you,” Nature Biotechnology, vol. 24, no. 8, pp. 914–916, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. D. Trudel, G. Zafarana, J. Sykes, C. L. Have, R. G. Bristow, and T. van der Kwast, “4FISH-IF, a four-color dual-gene FISH combined with p63 immunofluorescence to evaluate NKX3.1 and MYC status in prostate cancer,” The Journal of Histochemistry and Cytochemistry, vol. 61, no. 7, pp. 500–509, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Bylund, P. Stattin, A. Widmark, and A. Bergh, “Predictive value of bcl-2 immunoreactivity in prostate cancer patients treated with radiotherapy,” Radiotherapy and Oncology, vol. 49, no. 2, pp. 143–148, 1998. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Abdel-Wahab, B. A. Berkey, A. Krishan et al., “Influence of number of CAG repeats on local control in the RTOG 86-10 protocol,” American Journal of Clinical Oncology, vol. 29, no. 1, pp. 14–20, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. M. Roach III, M. De Silvio, T. Rebbick et al., “Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial,” International Journal of Radiation Oncology, Biology, Physics, vol. 69, no. 1, pp. 79–87, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. A. S. Ishkanian, G. Zafarana, J. Thoms, and R. G. Bristow, “Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer,” Acta Oncologica, vol. 49, no. 7, pp. 888–894, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. N. Erho, A. Crisan, I. A. Vergara et al., “Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy,” PLoS ONE, vol. 8, no. 6, Article ID e66855, 2013. View at Publisher · View at Google Scholar · View at Scopus
  75. C.-L. Wu, B. E. Schroeder, X.-J. Ma et al., “Development and validation of a 32-gene prognostic index for prostate cancer progression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 15, pp. 6121–6126, 2013. View at Publisher · View at Google Scholar · View at Scopus
  76. D. Knezevic, A. D. Goddard, N. Natraj et al., “Analytical validation of the Oncotype DX prostate cancer assay—a clinical RT-PCR assay optimized for prostate needle biopsies,” BMC Genomics, vol. 14, article 690, 2013. View at Publisher · View at Google Scholar · View at Scopus
  77. J. Cuzick, G. P. Swanson, G. Fisher et al., “Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study,” The Lancet Oncology, vol. 12, no. 3, pp. 245–255, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Yue, J. Li, S. Lee et al., “Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness,” Cell Metabolism, vol. 19, no. 3, pp. 393–406, 2014. View at Publisher · View at Google Scholar
  79. J. A. Watkins, S. Irshad, A. Grigoriadis, and A. N. J. Tutt, “Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers,” Breast Cancer Research, vol. 16, no. 3, article 211, 2014. View at Publisher · View at Google Scholar · View at Scopus
  80. D. Manson-Bahr, R. Ball, G. Gundem et al., “Mutation detection in formalin-fixed prostate cancer biopsies taken at the time of diagnosis using next-generation DNA sequencing,” Journal of Clinical Pathology, vol. 68, no. 3, pp. 212–217, 2015. View at Publisher · View at Google Scholar
  81. S. Carreira, A. Romanel, J. Goodall et al., “Tumor clone dynamics in lethal prostate cancer,” Science Translational Medicine, vol. 6, no. 254, Article ID 254ra125, 2014. View at Publisher · View at Google Scholar